About The ADCS
The Alzheimer's Disease Cooperative Study (ADCS)
was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and
the University of California, San Diego. The ADCS is a major initiative for Alzheimer's disease (AD)
clinical studies in the Federal government, addressing treatments for both cognitive and behavioral symptoms.
This is part of the NIA Division of Neuroscience's effort to facilitate the discovery, development and
testing of new drugs for the treatment of AD and also is part of the Alzheimer's Disease Prevention Initiative.
The ADCS was developed in response to a perceived need to advance research in the
development of drugs that might be useful for treating patients with Alzheimer's
disease (AD), particularly drugs that might not be developed by industry. As such,
the mandate of the ADCS is to:
Improve cognition, slow the rate of decline, or delay the appearance of AD.
Develop studies for promising agents designed to ameliorate behavioral symptoms.
Design new instruments for use in clinical studies.
Conceive of novel and innovative approaches to clinical study design and AD clinical study analysis.
Expand the range of patients studied in AD studies.
Enhance the recruitment of minority groups into AD studies.
The ADCS focuses on evaluating compounds that will benefit the general good of AD patients.
This includes the testing of agents that lack patent protection, are under patent protection
but are already marketed for other indications but where the agent may be useful in treating
AD, and are novel compounds developed by individuals, academic institutions and drug